Introduction
Hormonal and antihormonal manipulations have been used in the palliative treatment of advanced breast cancer with increasing frequency since the first experiments of Beatson in 1895.
Androgen therapy commenced in the 1930s, followed by oestrogen therapy, and in the 1950s surgical ablation of the adrenals and of the pituitary became widely adopted as effective if drastic interventions. All produced similar anticancer effects but with different attendant costs to the patient. Tamoxifen (Dentón 1996) Fig. 1 .
The instrument is now being widely used. In a study of the results in the Edinburgh clinic the results of prospective recording of toxicities of tamoxifen and other antihormones are of interest. In Fig. 2 it is shown that weight gain, hot flushes and fluid reten¬ tion were common problems affecting between onethird and nearly half of all patients. These problems occur in pre-and postmenopausal patients alike and are seen in patients on any of the currently available hormonal therapies. Sexual function (libido loss and/or vaginal symptoms) may not readily be volun¬ teered by patients to their often male doctors, but they are common and raise the possibility of specific discussion at clinic with either a doctor or probably, preferably, a nurse.
Because of the apparent frequency of tamoxifenassociated problems, a specific control group, agematched and not on hormone replacement therapy, was identified and contrasted against the preand postmenopausal tamoxifen-treated group. This 
